Literature DB >> 28693772

Response.

Robert A Balk1, Sameer S Kadri2, Zhun Cao3, Scott B Robinson3, Craig Lipkin3, Samuel A Bozzette4.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28693772      PMCID： PMC6026270          DOI： 10.1016/j.chest.2017.04.180

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  5 in total

1.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.

Authors:  Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

2.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuck Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

3.  Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States.

Authors:  Robert A Balk; Sameer S Kadri; Zhun Cao; Scott B Robinson; Craig Lipkin; Samuel A Bozzette
Journal:  Chest       Date:  2016-08-25       Impact factor: 9.410

4.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

Authors:  Evelien de Jong; Jos A van Oers; Albertus Beishuizen; Piet Vos; Wytze J Vermeijden; Lenneke E Haas; Bert G Loef; Tom Dormans; Gertrude C van Melsen; Yvette C Kluiters; Hans Kemperman; Maarten J van den Elsen; Jeroen A Schouten; Jörn O Streefkerk; Hans G Krabbe; Hans Kieft; Georg H Kluge; Veerle C van Dam; Joost van Pelt; Laura Bormans; Martine Bokelman Otten; Auke C Reidinga; Henrik Endeman; Jos W Twisk; Ewoudt M W van de Garde; Anne Marie G A de Smet; Jozef Kesecioglu; Armand R Girbes; Maarten W Nijsten; Dylan W de Lange
Journal:  Lancet Infect Dis       Date:  2016-03-02       Impact factor: 25.071

Review 5.  Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.

Authors:  Anna Prkno; Christina Wacker; Frank M Brunkhorst; Peter Schlattmann
Journal:  Crit Care       Date:  2013-12-11       Impact factor: 9.097
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.